A meta-analysis of cisplatin-based concurrent chemoradiotherapy with or without cetuximab for locoregionally advanced nasopharyngeal carcinoma.
Medicine (Baltimore)
; 98(42): e17486, 2019 Oct.
Article
em En
| MEDLINE
| ID: mdl-31626102
ABSTRACT
BACKGROUND:
It is unclear whether cetuximab (CTX) plus cisplatin-based concurrent chemoradiotherapy (CCRT) delivers equivalent or improved results over standard CCRT in locoregionally advanced nasopharyngeal carcinoma (NPC).METHODS:
The strategy involved searching the PubMed, Embase, Cochrane Library, and Web of Science. Pooled hazard ratios (HRs) for overall survival (OS), distant metastasis-free survival (DMFS), locoregional relapse-free survival (LRFS), and disease-free survival (DFS), and pooled risk ratios for adverse events were meta-analyzed.RESULTS:
In all, 1744 patients in 5 clinical trials were included in the analysis. Compared with CCRT group, CTX plus CCRT significantly improved DFS (HRâ=â0.59, 95% confidence interval [CI] 0.41-0.86, Pâ=â.006) and distant metastasis failure-free survival (HRâ=â0.54, 95% CI 0.38-0.76, Pâ=â.0004), rather than OS (HRâ=â0.70, 95% CI 0.44-1.09, Pâ=â.12) and local-regional failure-free survival (HRâ=â0.82, 95% CI 0.54-1.22, Pâ=â.33).CONCLUSIONS:
CTX plus CCRT might achieve higher DFS and DMFS with no significant difference in OS and LRFS. CTX plus CCRT group was associated with more grade 3-4 skin rash, mucositis and dermatitis. Large randomized trials were urgent to fully explore the usefulness of this treatment in the locally advanced NPC patients.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Nasofaríngeas
/
Cisplatino
/
Quimiorradioterapia
/
Cetuximab
/
Carcinoma Nasofaríngeo
/
Antineoplásicos
Tipo de estudo:
Clinical_trials
/
Systematic_reviews
Limite:
Humans
Idioma:
En
Revista:
Medicine (Baltimore)
Ano de publicação:
2019
Tipo de documento:
Article